Biochemical abnormalities associated with the development of multiple myeloma have been dicult to de®ne especially in terms of demonstrating an in vivo eect of suspected lesions. Herein, we have identi®ed such a defect associated with lack of expression of PTEN, a cellular phosphatase involved in the regulation of phosphatidylinositol phosphates (PIP's). In myeloma cells, PIP's are required for phosphorylation of Akt, a key event leading to inhibition of apoptosis. Loss of PTEN results in a failure to de-phosphorylate PIP's and a corresponding increase in Akt phosphorylation. OPM-2 cells lacking PTEN expression have the highest level of Akt phosphorylation of eight lines examined. Loss of PTEN was found to be associated with a 630 bp deletion corresponding to amino acids 56 ± 267. Ectopic expression of wild type PTEN in OPM-2 cells inhibited Akt phosphorylation which was correlated with an increase in apoptosis. The in vivo relevance of loss of PTEN expression was demonstrated by injecting control and wild type PTEN transfected OPM-2 cells into SCID mice. Tumors arose at an incidence of 100% in controls, but only 50% (and of smaller size and longer latency) in low PTEN expressing clones. Importantly, clones expressing high levels of PTEN failed to produce tumors even at ®ve times the latency period of controls. These results demonstrate that PTEN deletion/mutation is responsible for in vivo growth of this tumor and suggests that PTEN regulation may play an important role in tumor development in a subset of multiple myeloma patients. Oncogene (2000) 19, 4091 ± 4095.
Introduction
Multiple myeloma (MM) is a neoplasia of end stage B lineage cells. The disease initially is diagnosed by the accumulation of abnormal plasma cells in the bone marrow accompanied by the presence of a monoclonal immunoglobulin (Kyle, 1992; Seiden and Anderson, 1994) . Patients generally respond to standard chemotherapy regimens and enter a quiescent phase that lasts, on average, 3 ± 5 years. Virtually all patients relapse following this period, enter a blast phase during which tumor cells may leave the bone marrow and seed a variety of organs and eventually die from disease complications (Kyle, 1992; Anderson et al., 1999; Munshi et al., 1999) . The sequence of a quiescent plateau followed by an expanding blast phase suggests the accumulation of mutations that lead to disease progression. In spite of extensive study, very little is known about genetic lesions that contribute to either the origin or progression of MM. Unlike other hematologic malignancies which have characteristic genetic lesions that have been directly implicated in neoplastic development (i.e. the Bcl-2 translocation in CML), such lesions have not been identi®ed in MM. During the past few years, a number of translocations have been described in MM such as those involving the immunoglobulin locus and a non-random chromosomal partner (Bergsagel et al., 1996; Richelda et al., 1997) . However, the biological signi®cance of such translocations has yet to be determined. In a similar context, mutations such as those found in p53 and Ras which have been observed in other cancers have not been consistently noted in MM (Ladanyi et al., 1992; Yasuga et al., 1995) .
While biochemical lesions involved in MM have been dicult to elucidate, numerous studies have implicated IL-6 as a major factor involved in survival of MM cells (Klein et al., 1990; Klein and Bataille, 1992) . Additional investigations have suggested a similar role for insulin-like growth factor-I (IGF-I) (Freund et al., 1994; Georgii-Hemming et al., 1996; Uddin et al., 1996; Jelinek et al., 1997) and we have recently characterized the biochemical pathway involved in IGF-I responsiveness of MM cells (Ge and Rudiko, 2000) . During the course of these studies, we have analysed the PTEN gene product, a tumor suppressor responsible for regulation of phosphatidylinositol phosphates (PIP's). Herein, we describe a mutation resulting in lack of expression of PTEN and demonstrate a direct role for this lesion in myeloma growth in vivo.
Results

PTEN expression is inversely correlated with Akt phosphorylation
In a recent study (Ge and Rudiko, 2000) , we have demonstrated that Akt was highly expressed in eight of eight MM cell lines and IGF-I-dependent Akt phosphorylation was observed in seven of eight of these. As Akt is activated following phosphorylation by PIP's, we examined the relationship between Akt phosphorylation state and PTEN, a phosphatase regulating PIP's. Western blot analysis (Figure 1 ) demonstrates the presence of Akt in ®ve MM lines and IGF-I-dependent phosphorylation on Ser 473 in four. The level of Akt phosphorylation is variable, but markedly higher in OPM-2 than the other lines. Analysis of PTEN revealed a lack of expression in Oncogene (2000) 19, 4091 ± 4095 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc OPM-2. PTEN expression was highest in ANBL-6 and Brown correlating with the lowest levels of Akt phosphorylation. Thus, Akt phosphorylation is inversely correlated with PTEN expression level.
PTEN deletion in OPM-2 cells
Since PTEN protein expression was not detected in OPM-2 cells, we next examined PTEN mRNA by RT ± PCR (Figure 2 ) using PCR primer pairs¯anking the entire coding region. Size of the PCR product in OPM-2 cells was about 630 bp shorter than the expected full length product seen in all other lines. DNA sequence analysis revealed a deletion encompassing amino acids 56 ± 267. The deletion also resulted in a frameshift producing a termination codon 22 bp after the frameshift. 
Apoptotic effect of wt-PTEN
As we have recently reported that activation of Akt leads to phosphorylation of Bad (Ge and Rudiko, 2000) , an anti-apoptotic signal, we next examined the eect of wild type PTEN expression on apoptosis in the PTEN transfected and control cells. As seen in Figure 4 , parental OPM-2 and vector transfected controls showed similar levels of caspase 3 activity which was decreased 14 and 37%, respectively in response to IGF-I. However, in PTEN transfected cells caspase 3 activity was increased 2.5-fold and could be reduced by 45% upon IGF-I stimulation. Thus, expression of PTEN markedly increased apoptotic activity in these cells.
To test whether expression of PTEN was important for in vivo tumor growth, both low and high PTEN expressing clones were injected into SCID mice along with vector only controls (Table 1) . Control mice developed large, palpable tumors (100% incidence) in 10 ± 15 days. In contrast, tumors arose in only two of four animals in the low PTEN group. The latency of these tumors was twice that observed in the controls and tumor volume was approximately 10 times less than that of controls. Importantly, no tumors were observed in the high PTEN group even after 70 days.
Discussion
Biochemical lesions that contribute to the development or progression of MM have been dicult to identify. Some associative correlations have been described, such as non-random chromosomal translocations (Bergsagel et al., 1996; Richelda et al., 1997; Gabrea et al., 1999) , but direct demonstration of a role in malignancy for genes near these sites has been elusive. Similarly, mutations in genes frequently observed in other cancers such as p53 and Ras (Portier et al., 1992; Yasuga et al., 1995) have not been consistently observed in myeloma. As part of an analysis of the IGF-I pathway in MM, we have recently examined expression of the PTEN gene product. Herein, we describe a MM line in which PTEN is mutated and not expressed and demonstrate that this loss of expression eects apoptosis leading directly to in vivo tumor growth.
PTEN is a novel tumor suppressor gene containing sequence motifs with homology to the protein tyrosine phosphatase (PTP) family and to two cytoskeletal proteins, tensin and auxilin (Li and Sun, 1997; Steck et al., 1997) . It has been reported that PTEN is mutated/deleted in a wide variety of tumors including glioblastomas, endometrial tumors, melanoma, and breast and prostate cancers (Risinger et al., 1997; Boni et al,. 1998; Haas-Kogan et al., 1998; Davies et al., 1999; Ghosh et al., 1999) . Germ-line mutations of PTEN have also been suggested as the underlying genetic lesion in Cowden disease , an inherited autosomal syndrome characterized by increased incidence of breast and thyroid tumors; and in Bannaya-Zonana Syndrome, a disorder characterized by intestinal hamartomas and neurological abnormalities . In vivo studies in mouse models have demonstrated that heterozygous PTEN disruption causes hyperplastic-dysplastic changes in the prostate, skin and colon, similar to those observed in Cowden disease (Di Cristofano et al., 1998; Suzuki et al., 1998) , providing additional evidence for the role of PTEN in tumor suppression.
In vitro studies have shown that recombinant PTEN functions to dephosphorylate the product of PI-3K activation, phosphatidylinositol 3,4,5-triphosphate (Ptd-Ins-3,4,5, PI-P 3 ) (Cantley and Neel, 1999) leading to a decrease or absence in phosphorylation of downstream PI-3K targets. We have recently described the biochemical pathways in MM cells activated upon IGF-I stimulation (Ge and Rudiko, 2000) . Signaling through IGF-I involves one cascade including IGF-IR, IRS-1, PI-3K, Akt, and Bad. Generation of PI-P 3 following activation of PI-3K leads to successive phosphorylation of Akt and Bad. Phosphorylation of Bad results in dissociation of Bad-Bcl 2 complexes allowing Bcl 2 to exert an anti-apoptotic eect (Yang et al., 1995; Peruzzi et al., 1999) . Thus, PTEN is likely to play a critical role in this pathway by regulating levels of PI-P 3 .
A survey of MM lines (Figure 1 ) revealed varying levels of Akt phosphorylation in response to IGF-I stimulation. Akt phosphorylation inversely correlated with the level of PTEN expression with the highest levels detected in OPM-2 wherein no PTEN was detected. RT ± PCR analysis revealed a smaller than expected product that, upon sequence determination, was revealed to have a deletion corresponding to 212 amino acids accompanied by a frameshift leading, additionally, to a premature stop codon. To examine the biological consequence of PTEN loss, parental cells were transfected with a construct encoding wild type PTEN. In transfected clones, Akt phosphorylation was inversely correlated with the level of PTEN expression. Clones expressing high levels of PTEN (and consequently low Akt phosphorylation) exhibited a marked increase in caspase activity which could be reduced *50% upon IGF-I treatment. The critical role of PTEN in tumor growth was demonstrated by injecting control and PTEN expressing clones into SCID mice. Parental cells rapidly produced tumors in 100% of animals. Transfectants expressing low levels of PTEN gave rise to tumors in only 50% of animals and these tumors were delayed in appearance and 10-fold smaller in size. Strikingly, no tumors were observed in cells expressing high levels of PTEN even at ®ve times the latency period of controls. Thus, the loss of PTEN expression in OPM-2 permits in vivo growth of this tumor and tumor growth can be reversed in a dosedependent fashion by increasing amounts of this protein.
The present studies have de®ned an important role for PTEN in myeloma cell growth and represent one of the few examples in which a biochemical lesion has been demonstrated to directly eect in vivo tumor cell growth. However, it is unclear at this time whether PTEN abnormalities will prove important in more than a subset of MM. Of eight lines studied to date, two, including OPM-2, have been found to react abnormally with speci®c antibodies although we have yet to de®ne a molecular defect associated with the second occurrence. Alternatively, in a broader sense these results may indicate that a variety of mutations occurring anywhere in this (or other) signaling cascade(s) may produce the same phenotypic result. As a consequence, common lesions may prove to be much rarer in MM as opposed to a variety of defects in certain critical pathways that can produce a similar tumor type that is dependent on the target cell in which the mutation occurs.
Materials and methods
Cell lines
Human MM lines used in the present studies were obtained from Dr Michael Kuehl, National Cancer Institute. Cells were cultured in RPMI 1640 (Bio¯uids, Rockville, MD, USA) supplemented with 10% fetal bovine serum (FBS, Bio¯uids, Rockville, MD, USA), 100 units/ml penicillin and 50 mg of streptomycin/ml. ANBL-6 is IL-6-dependent and was grown in medium containing 10 ng/ml of IL-6. All other lines are IL-6-independent.
Western blots
Cells (1610 7 ) were grown in serum-free media for 18 h, stimulated with human IGF-I (100 ng/ml) for 10 min at 378C, washed twice with cold PBS containing 1 mM Na 3 VO 4 and 1 mM NaF, and then lysed on ice for 30 min by addition of 1 ml cold lysis buer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 2.5 mM EDTA, 10 mM NaPPi, 1 mM NaF, 1 mM Na 3 VO 4 , 1 mM 4-(2-aminoethyl)-benzenesulfonyl uoride hydrochloride (AEBSF), 20 mg/ml aprotinin and 20 mg/ml leupeptin). Cell debris was removed by centrifugation at 12 000 g for 30 min at 48C. Western blots were performed on total cell lysates with antibodies to PTEN (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and Akt (New England Biolabs, Beverly, MA, USA). Proteins were fractionated on 8% SDS ± PAGE gels, and transferred to PVDF membranes (Millipore, Bedford, MA, USA) for blotting. Protein detection was performed by ECL using an HRP-conjugated secondary antibody.
RT ± PCR and sequencing
Total RNA was extracted from the cells using an RNeasy Mini Kit from Qiagen (Valencia, CA, USA). First strand cDNA was generated from 1 mg of total RNA using an oligodT primer and Superscript II reverse transcriptase (Clontech, Palo Alto, CA, USA). A primer pair spanning the entire PTEN coding sequence was used for PCR: Forward, 5'-GACAGCCATCATCAAAGAGATCG-3'; Backward, 5'-CATGGTGTTTTATCCCTCTTG-3'. PCR was performed using Taq polymerase (Qiagen) for 35 cycles. PCR products were fractionated on a 1% agarose gel and visualized by ethidium bromide staining. Ampli®ed bands were cut from the gel and DNA was puri®ed using a QIAquick gel extraction kit from Qiagen. Sequences were determined using an ABI PRISM 1 BigDye TM Terminator Cycle Reaction Kit (PE Applied Biosystems, Foster City, CA, USA) at the NCI DNA Sequencing Minicore.
Expression plasmid and transfection of OPM-2 cells
A full length wild type human PTEN cDNA in pBluescript SK+ was obtained from Dr Peter Steck (MD Anderson Cancer Center, Houston, TX, USA). The PTEN coding sequence was excised with XbaI and BamHI and subcloned into pCEP4, an EBV-based episomal mammalian expression vector from Invitrogen (Carlsbad, CA, USA). The subcloned pCEP4 expressing wt PTEN was designated as pCEP4-wtPTEN. Puri®ed pCEP4-wtPTEN and pCEP4 plasmid DNA were transfected into OPM-2 cells, respectively, using DMRIE-C reagent from Life Technologies (Gaithersburg, MD, USA). Positive clones were selected using hygromycin B. PTEN protein expression levels were determined using anti-PTEN antibody (C-20) (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Caspase-3 activity assay
For detection of apoptotic activity in IGF-I non-stimulated or stimulated cells, an assay kit, ApoAlert Caspase-3 Assay Kit from Clontech (Palo Alto, CA, USA) was used. Brie¯y, parental OPM-2 cells, or transfected clones were washed with PBS, resuspended in serum-free media and cultured in 6-well plates with or without 100 ng/ml of IGF-I at a density of 1610 6 /well for 4 days. Cells were lysed in 50 ml of chilled cell lysis buer for 10 min. Cell debris was removed by centrifugation at 12 000 r.p.m. for 5 min. The supernatant was incubated with colorimetric conjugated substrate, chromophore p-nitroanilide (pNA), for 1 h at 378C. Relative OD values were determined at 405 nm and protease activity represented as relative OD.
In vivo tumorigenesis studies OPM-2 cells transfected with pCEP4-wtPTEN or pCEP4 were cultured in media containing 0.4 mg/ml hygromycin B. Cells were washed with PBS three times before inoculation into SCID mice. Each mouse was injected with 1610 7 transfected OPM-2 cells intraperitoneally and animals monitored twice a week for tumor growth. The control group (vector only) was sacri®ced at day 30 due to the presence of large, palpable tumors. Animals in the PTEN group were sacri®ced at day 80. Tumor volume was determined by measurement of the largest diameter and the diameter at a right angle.
